Press kit
LifeLeaf, by LifePlus.
Blood sugar and heart health, together on your wrist.
No needle, no cuff, and nothing to replace. Light-based sensing and AI trained against clinical reference devices turn what the wrist gives back into trends, three daily scores and one action a day.
LifePlus, Inc. is based in San Jose, California. Its results have been presented at ADA, ATTD, ESH and the American Heart Association, and published in Diabetes, Diabetes Technology & Therapeutics and the Journal of Hypertension.
See it working
See it working, in one card.
A journalist writing about a needle-free blood-sugar wearable has one problem: the product is invisible. This is the asset that makes the claim legible at a glance — the app’s own See it working card, shown here as it renders on device.
Image caption
Illustrative.
The published research
Four studies. Every citation in full.
The full study record — institutions, populations, and the abstract-versus-poster distinction stated plainly — lives on the clinical evidence page. The internal blood-pressure analysis does not appear in the press kit: it is unpublished, and only the published ESH figures are cited here.
The diverse-population story
A 2025 study in Diabetes tested the sensor across 248 people in 12 countries. Optical wrist sensing performing unequally across skin tones is a documented weakness of the whole category — the app’s skin-tone assessment step, shown here, is how LifeLeaf answers that with its own data.
Traction
2,200 units contracted and 11,000+ committed through distribution partners in Asia, the Middle East and Europe.
Investor deck v5, 9 September 2026, slide 12.
How to describe LifeLeaf
Accurate
- General wellness device
- Shows blood sugar and blood-pressure trends
- Blood pressure shown as an hourly average, not a spot reading
- Tested against reference standards at Mayo Clinic, Cleveland Clinic Abu Dhabi and AMCR Institute (UC San Diego)
- No needle, no cuff, no consumables
- Published in Diabetes, Diabetes Technology & Therapeutics and the Journal of Hypertension
- Presented at ADA, ATTD, ESH and the American Heart Association
- 70,000+ paired readings collected across seven clinical sites
Please don’t write
- FDA-cleared or FDA-approved
- Medical-grade or clinical-grade
- Clinically proven
- A CGM replacement
- Approved, endorsed or partnered with any institution
- More accurate than any named device
- That it monitors, diagnoses or manages any condition
- That any team member’s former regulatory role implies FDA involvement
Assets & contact
Media contact.
The device render and app screens shown above retain their display conventions. For image-use requests or an interview, contact us below.
Free to join — or reserve now for $2 to lock founder pricing.